Description: Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
Home Page: dimerix.com
425 Smith Street
Fitzroy,
VIC
3065
Australia
Phone:
1300 813 321
Officers
| Name | Title |
|---|---|
| Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. | CEO, MD & Director |
| Dr. David Everett Fuller BPharm, M.D., MBBS | Chief Medical Officer |
| Mr. Robert Shepherd | Chief Commercialisation Officer |
| Mr. Hamish George B.Com., C.A. | CFO & Company Secretary |
| Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. | Chief Scientific Advisor |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.5108 |
| Price-to-Sales TTM: | 253.3532 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |